Laura Brege, a director at Mirum Pharmaceuticals (NASDAQ:MIRM), sold common stock worth approximately $1.33 million on November 11, 2026, according to Investing.com.
The sales followed the exercise of stock options at $16.71 per share, which the report says were fully vested. Brege sold 14,167 shares in two blocks. The first block, 10,907 shares, sold at a weighted average price of $94.05. The second, 3,260 shares, sold at a weighted average price of $94.74. After the transactions, she directly holds 15,703 shares, the report says.
The report says the stock traded at $93.99 at the time of the article, near the transaction prices. It also says the shares returned 31.6% over the past year. The report cites InvestingPro analysis suggesting the stock is slightly overvalued at current levels.
The report also summarizes recent company results. Mirum reported third-quarter 2026 net product sales of $185.7 million, up 40% year over year and 5% quarter over quarter, above a consensus estimate of $178.1 million. It posted an EPS of -$0.87, below an analyst estimate of -$0.49, and raised its 2026 sales outlook.
Analysts cited in the report include H.C. Wainwright, which reiterated a Buy rating and a $202 price target after positive Phase 3 results for brelovitug in chronic hepatitis delta. Raymond James raised its price target to $189, and Citizens raised its target to $167.